|

Breast Cancer Clinical Trials in Charlotte, NC

46 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPhase 3<1 mi
The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyPhase 3<1 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3<1 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3<1 mi
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Phase 3<1 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3<1 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—<1 mi
National Cancer Institute "Cancer Moonshot Biobank"—<1 mi
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3<1 mi
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsPhase 1<1 mi
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerPhase 3<1 mi
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyPhase 2<1 mi
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Phase 3<1 mi
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerPhase 1<1 mi
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic TherapyN/A<1 mi
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerPhase 1/2<1 mi
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Phase 3<1 mi
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)—<1 mi
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer—<1 mi
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerPhase 1/2<1 mi
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and MelanomaPhase 1<1 mi
Utility of a Mobile Application for Young Women With Breast CancerN/A<1 mi
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Phase 3<1 mi
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment—<1 mi
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesPhase 1/2<1 mi
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H MutationPhase 1<1 mi
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving ImmunotherapyN/A<1 mi
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesPhase 1/213 mi
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4Phase 113 mi
Study of INCB123667 in Subjects With Advanced Solid TumorsPhase 113 mi
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid TumorsPhase 113 mi
A Study to Investigate APL-5125 in Adults With Advanced Solid TumorsPhase 1/213 mi
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsPhase 1/213 mi
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsPhase 113 mi
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasPhase 113 mi
Study of XB010 in Subjects With Solid TumorsPhase 113 mi
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or BevacizumabPhase 113 mi
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsPhase 1/213 mi
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN TrialsN/A20 mi
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/A20 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 320 mi
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerPhase 320 mi
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation—23 mi
Increasing Germline Genetic Testing for Patients With CancerN/A37 mi
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsN/A47 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—47 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.